An AI-based spatial analysis of the tumor microenvironment has identified immune cell markers that can accurately predict which intermediate-risk breast cancer ... (opens in new tab)

Research led by RCSI University of Medicine and Health Sciences and University College Dublin (UCD) has identified immune markers that could help doctors more accurately determine which breast cancer patients are unlikely to benefit from chemotherapy, potentially sparing some patients from unnecessary treatment.